<?xml version="1.0" encoding="UTF-8"?>
<p id="p0350">Moreover, MSCs might improve ARDS, regenerate lung tissue, and lessen lung fibrosis through secreting IL-10, vascular endothelial growth factor (VEGF), keratinocyte growth factor (KGF), and hepatocyte growth factor (HGF) in SARS-CoV-2 patients 
 <xref rid="b0650" ref-type="bibr">[130]</xref>. It is possible that MSC-based therapy could remove the need for ventilation in COVID-19 patients, return the T cell counts to a normal range, restore pulmonary function, decrease the level of inflammatory cytokines, and increase the level of anti-inflammatory cytokines 
 <xref rid="b0655" ref-type="bibr">[131]</xref>, 
 <xref rid="b0660" ref-type="bibr">[132]</xref>.
</p>
